GlassScriptPhysician profile
Adam Swigost
NPI 1861996233
$4,472.33
in general payments reported to CMS, 2019-2025
23 companies · $901 in 2025
The $901 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $780 · 2023: $1,620 · 2024: $1,171 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,286 · Education: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,286.09 |
| Education | $405.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $920.51 | 2022-2025 | Skyrizi, Rinvoq, Botox |
| Janssen Biotech, INC. | $725.00 | 2024-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $468.81 | 2023-2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $345.38 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $313.03 | 2022-2025 | Epsolay, Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $228.46 | 2023-2024 | Ilumya, Winlevi |
| Regeneron Healthcare Solutions, INC. | $219.61 | 2022-2025 | Dupixent, Libtayo |
| Pfizer INC. | $212.74 | 2022-2025 | |
| Leo Pharma INC. | $172.89 | 2022-2024 | Adbry |
| Revance Therapeutics, INC. | $107.51 | 2024 | Daxxify |
| Sanofi-Aventis U.S. LLC | $99.00 | 2023 | |
| Amgen INC. | $89.86 | 2022-2025 | Otezla, Enbrel, Otezla |
| Dermavant Sciences, INC. | $89.72 | 2022-2023 | Vtama |
| Lilly USA, LLC | $72.77 | 2024-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $71.98 | 2022-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $65.84 | 2025 | Nexplanon, Vtama |
| Incyte Corporation | $57.09 | 2023-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $52.23 | 2023 | |
| Allergan, INC. | $49.68 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.97 | 2022-2024 | Spevigo |
| Ucb, INC. | $32.47 | 2022-2024 | Bimzelx |
| Almirall LLC | $20.05 | 2023 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.73 | 2025 | Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Swigost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.